Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Citigroup Inc. stock logo
C
Citigroup
$63.03
-12.2%
$76.08
$53.51
$84.74
$118.62B1.4313.83 million shs39.44 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$788.62
-3.6%
$849.30
$711.40
$972.53
$747.75B0.343.30 million shs2.67 million shs
The Medicines Company stock logo
MDCO
Medicines
$84.90
$84.90
$17.81
$84.98
$6.77B1.19.55 million shsN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$67.08
-1.7%
$81.36
$65.25
$148.15
$301.04B0.425.59 million shs8.82 million shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Citigroup Inc. stock logo
C
Citigroup
-12.23%-12.34%-12.77%-11.23%+2.15%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-3.78%-4.08%-13.43%+0.85%+1.59%
The Medicines Company stock logo
MDCO
Medicines
0.00%0.00%0.00%0.00%0.00%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-1.64%-4.41%-23.24%-23.46%-47.17%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Citigroup Inc. stock logo
C
Citigroup
4.9898 of 5 stars
4.43.02.52.62.62.55.0
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9174 of 5 stars
3.45.03.34.03.22.51.9
The Medicines Company stock logo
MDCO
Medicines
N/AN/AN/AN/AN/AN/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.8224 of 5 stars
4.45.02.50.02.70.04.4
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Citigroup Inc. stock logo
C
Citigroup
2.73
Moderate Buy$83.3032.17% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$1,009.7228.04% Upside
The Medicines Company stock logo
MDCO
Medicines
0.00
N/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.80
Moderate Buy$145.25116.52% Upside

Current Analyst Ratings Breakdown

Latest LLY, C, NVO, and MDCO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2025
Citigroup Inc. stock logo
C
Citigroup
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$85.50 ➝ $75.50
4/2/2025
Citigroup Inc. stock logo
C
Citigroup
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$90.00 ➝ $89.00
4/1/2025
Citigroup Inc. stock logo
C
Citigroup
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$79.00 ➝ $76.00
3/19/2025
Citigroup Inc. stock logo
C
Citigroup
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$90.00 ➝ $80.00
3/13/2025
Citigroup Inc. stock logo
C
Citigroup
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$110.00 ➝ $109.00
3/13/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
3/3/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
2/12/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight
2/3/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1,029.00 ➝ $1,038.00
(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Citigroup Inc. stock logo
C
Citigroup
$81.09B1.46$6.81 per share9.25$101.26 per share0.62
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B16.60$12.86 per share61.34$15.05 per share52.40
The Medicines Company stock logo
MDCO
Medicines
$6.14M1,102.36N/AN/A($0.30) per share-283.00
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$290.40B1.04$3.11 per share21.57$4.64 per share14.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Citigroup Inc. stock logo
C
Citigroup
$12.68B$5.9510.596.670.647.43%6.62%0.53%4/15/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7167.3525.341.4023.51%85.24%16.19%5/1/2025 (Estimated)
The Medicines Company stock logo
MDCO
Medicines
-$123.16M-$2.91N/AN/AN/AN/AN/A-25.70%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.2920.3914.400.9034.81%84.68%26.29%5/1/2025 (Estimated)

Latest LLY, C, NVO, and MDCO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64N/AN/AN/A$12.77 billionN/A
5/1/2025N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.92N/AN/AN/AN/AN/A
4/15/2025N/A
Citigroup Inc. stock logo
C
Citigroup
$1.84N/AN/AN/A$21.34 billionN/A
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/5/2025Q4 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.88$0.91+$0.03$0.91N/AN/A
1/15/2025Q4 24
Citigroup Inc. stock logo
C
Citigroup
$1.22$1.34+$0.12$1.34$19.51 billion$19.58 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Citigroup Inc. stock logo
C
Citigroup
$2.243.55%+2.24%37.65%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.76%+15.21%51.24%11 Years
The Medicines Company stock logo
MDCO
Medicines
N/AN/AN/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.572.34%+25.26%47.72%N/A

Latest LLY, C, NVO, and MDCO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/3/2025
Citigroup Inc. stock logo
C
Citigroup
quarterly$0.563.55%5/5/20255/23/2025
2/5/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.78741.2%3/31/20253/31/20254/8/2025
1/14/2025
Citigroup Inc. stock logo
C
Citigroup
quarterly$0.563.04%2/3/20252/3/20252/28/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Citigroup Inc. stock logo
C
Citigroup
1.50
0.96
0.96
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
The Medicines Company stock logo
MDCO
Medicines
21.45
0.77
0.77
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.62
0.74
0.55

Institutional Ownership

CompanyInstitutional Ownership
Citigroup Inc. stock logo
C
Citigroup
71.72%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
The Medicines Company stock logo
MDCO
Medicines
N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Citigroup Inc. stock logo
C
Citigroup
0.08%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
The Medicines Company stock logo
MDCO
Medicines
8.41%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Citigroup Inc. stock logo
C
Citigroup
240,0001.88 billion1.89 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
The Medicines Company stock logo
MDCO
Medicines
6279.72 millionN/AOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.49 billion4.48 billionOptionable

Recent News About These Companies

Novo Nordisk: Not As Bullish As Many
Novo Nordisk announces changes in Executive Management

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Citigroup stock logo

Citigroup NYSE:C

$63.02 -8.74 (-12.17%)
Closing price 04/3/2025 03:58 PM Eastern
Extended Trading
$60.77 -2.26 (-3.58%)
As of 06:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Citigroup Inc., a diversified financial service holding company, provides various financial product and services to consumers, corporations, governments, and institutions worldwide. It operates through five segments: Services, Markets, Banking, U.S. Personal Banking, and Wealth. The Services segment includes Treasury and Trade Solutions, which provides cash management, trade, and working capital solutions to multinational corporations, financial institutions, and public sector organizations; and Securities Services, such as cross-border support for clients, local market expertise, post-trade technologies, data solutions, and various securities services solutions. The Markets segment offers sales and trading services for equities, foreign exchange, rates, spread products, and commodities to corporate, institutional, and public sector clients; and market-making services, including asset classes, risk management solutions, financing, prime brokerage, research, securities clearing, and settlement. The banking segment includes investment banking; advisory services related to mergers and acquisitions, divestitures, restructurings, and corporate defense activities; and corporate lending, which includes corporate and commercial banking. The U.S. Personal Banking segment provides co-branded cards and retail banking services. The Wealth segment provides financial services to high-net-worth clients through banking, lending, mortgages, investment, custody, and trust product offerings; and to professional industries, including law firms, consulting groups, accounting, and asset management. The company was founded in 1812 and is headquartered in New York, New York.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$788.62 -29.60 (-3.62%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$782.89 -5.73 (-0.73%)
As of 06:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Medicines stock logo

Medicines NASDAQ:MDCO

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$67.08 -1.16 (-1.70%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$65.22 -1.86 (-2.78%)
As of 06:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.